FDA/NIH dental MOU
This article was originally published in The Gray Sheet
Executive Summary
Memorandum of understanding between FDA and the National Institutes of Health's National Institute of Dental Research has as its "principal goal" the reduction of time between the research and development phase of a dental product's life cycle and its commercial availability, FDA says in a June 2 Federal Register notice. The MOU will "facilitate interactions between" NIDR and the agency regarding "improvements in the quality and relevance of pre-clinical and clinical research" on products for use in oral health care. By enhancing the quality of product-related research, the organizations will "facilitate and improve premarket evaluations"...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.